https://lymphoblastic-hub.com

Home | ALL HubOnline resource for healthcare professionals, providing information, news & support relating to ALLHome | ALL Hub You need to enable JavaScript to run this app. All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie PolicyYes, I accept cookiesIntroducingNow you can personaliseyour ALL Hub experience!Bookmark content to read laterSelect your specific areas of interestView content recommended for youCreate My ALL HubFind out more  TRANSLATEThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.Steering CommitteeAbout UsNewsletterContactVisit:AML HubGvHD HubLupus HubLymphoma HubMPN HubMultiple Myeloma HubPsOPsA HubLOADINGYou're logged in! Click here any time to manage your account or log out.Brought to you byLOADINGYou're logged in! Click here any time to manage your account or log out.VIEW ALL CONTENTSteering CommitteeAbout UsNewsletterContactTypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATESVIEW ALLALL TypesRelapsed/RefractoryALL by ageALL-related mutationsRiskSocioeconomicEpigenetic modifier mutationsChromosomal aberrationsLineageView all TypesVIEW ALL CONTENTAdd bookmarkTumor burden-guided dosing of obe-cel in patients with R/R B-cell ALL: Results from the FELIX trial We summarize results from the phase Ib/II FELIX trial of tumor burden-guided administration of obe-cel in adult patients with R/R B-ALL, as presented...Sep 24, 2024Add bookmarkToxicities associated with TKI maintenance therapy following allo-HSCT in patients with Ph+ ALL We summarize results from a retrospective analysis assessing the toxicities associated with TKI maintenance therapy post-allo-HSCT in 185 adult patients...Sep 20, 2024Add bookmarkPh-like ALL: An overview of the genomic landscape, epidemiology, diagnosis, and treatment Here, we provide an overview of the genomic landscape, epidemiology, diagnosis, and treatment strategies for Philadelphia chromosome-like ALL.Sep 16, 2024Add bookmarkDELPHINUS: Daratumumab plus chemotherapy in pediatric patients with R/R ALL or LLWe summarize results from the phase II DELPHINUS trial assessing daratumumab plus backbone chemotherapy in pediatric patients with R/R B-cell ALL, R/R T-cell ALL, and...Sep 16, 2024Hervé Dombret"In partnership with the European School of Haematology, the ALL Hub will contribute to the dissemination of knowledge and favor fruitful translational discussions in the field of ALL."Hervé Dombret"In partnership with the European School of Haematology, the ALL Hub will contribute to the dissemination of knowledge and favor fruitful translational discussions in the field of ALL."Featured ContentAdd bookmarkWhat is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific...Congressesview moreAdd bookmarkTumor burden-guided dosing of obe-cel in patients with R/R B-cell ALL: Results from the FELIX trial We summarize results from the phase Ib/II FELIX trial of tumor burden-guided administration of...Sep 24, 2024Add bookmarkSOHO 2024 live congress feed Stay up to date with the latest developments in ALL from the SOHO 2024 Annual Meeting with our live social media coverage.Sep 11, 2024Add bookmarkBrexu-cel for patients with R/R B-ALL: 4-year follow-up from the ZUMA-3 trial We summarize long-term survival outcomes with a 4-year follow-up from the ZUMA-3 trial of brexu-cel for patients with R/R...Aug 2, 2024Add bookmarkJZP458 in ALL/LBL: Post hoc analysis from AALL1931 trial We summarize results of the post hoc analysis from the AALL1931 trial assessing the safety of JZP458 in children and adult patients with...Jul 30, 2024Therapeuticsview moreAdd bookmarkTumor burden-guided dosing of obe-cel in patients with R/R B-cell ALL: Results from the FELIX trial We summarize results from the phase Ib/II FELIX trial of tumor burden-guided administration of...Sep 24, 2024Add bookmarkToxicities associated with TKI maintenance therapy following allo-HSCT in patients with Ph+ ALL We summarize results from a retrospective analysis assessing the toxicities associated with TKI...Sep 20, 2024Add bookmarkPh-like ALL: An overview of the genomic landscape, epidemiology, diagnosis, and treatment Here, we provide an overview of the genomic landscape, epidemiology, diagnosis, and treatment strategies for...Sep 16, 2024Add bookmarkDELPHINUS: Daratumumab plus chemotherapy in pediatric patients with R/R ALL or LLWe summarize results from the phase II DELPHINUS trial assessing daratumumab plus backbone chemotherapy in pediatric...Sep 16, 2024Most ReadAdd bookmarkThe 5th edition of the World Health Organization classification of haematolymphoid tumors: key updates to ALL classificationAdd bookmarkDaratumumab for relapsed/refractory T-cell ALL or LL: Results from DELPHINUS study Add bookmarkBrexu-cel for patients with R/R B-ALL: 4-year follow-up from the ZUMA-3 trial Add bookmarkBlinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial B-cell ALLview moreAdd bookmarkTumor burden-guided dosing of obe-cel in patients with R/R B-cell ALL: Results from the FELIX trial We summarize results from the phase Ib/II FELIX trial of tumor burden-guided administration of...Sep 24, 2024Add bookmarkDELPHINUS: Daratumumab plus chemotherapy in pediatric patients with R/R ALL or LLWe summarize results from the phase II DELPHINUS trial assessing daratumumab plus backbone chemotherapy in pediatric...Sep 16, 2024Add bookmarkManagement of complications of CAR T-cell therapies in EuropeWe summarize results from a survey by the EBMT designed to assess the management of CAR T-cell complications in patients with ALL,...Sep 13, 2024Add bookmarkBlinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial We summarize key findings from the third interim efficacy analysis of the phase III ECOG-ACRIN...Sep 9, 2024T-cell ALLview moreAdd bookmarkDELPHINUS: Daratumumab plus chemotherapy in pediatric patients with R/R ALL or LLWe summarize results from the phase II DELPHINUS trial assessing daratumumab plus backbone chemotherapy in pediatric...Sep 16, 2024Add bookmarkPatient- and transplant-related prognostic factors for post-transplant outcomes in patients with T-ALLWe summarize results from a retrospective analysis evaluating the impact of patient- and...Jun 25, 2024Add bookmarkSafety and efficacy of allo-HSCT for patients with R/R T-ALL/LBL who achieved CR after CD7-directed CAR T-cell therapyHere, we summarize a retrospective study published by Cao et al. on the safety...Jun 20, 2024Add bookmark2023 ELN recommendations Part 2: Clinical management of adult ALLHere, we summarize the 2023 ELN recommendations for the clinical management of adult ALL, including the application of MRD, management...May 21, 2024Most ViewedAdd bookmarkWhat are the geographical barriers to accessing specialty cancer care among adolescents and young adults with ALL?Add bookmarkWhat is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?Add bookmarkKey considerations when preparing patients with ALL for CAR T-cell therapy Add bookmarkIs next-generation sequencing a useful tool for the risk stratification of patients with T-ALL?Brought to you byDelivering streamlined independent medical education to enhance clinical practiceIn partnership withThank you to the funders of the ALL Hub. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.Interested in becoming a supporter? Please contact us.Terms and ConditionsCookie PolicyPrivacy PolicyNewsletterCopyright ©ALL Hub. 2021-2024. All rights reserved.All content on this site is intended for healthcare professionals only. If you are a patient or caregiver, please visit Know ALL.enen1727458812https://lymphoblastic-hub.com

Рэдагаваць свой сайт?

Што ты робіш